Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Capital Management Corp VA

Capital Management Corp VA trimmed its stake in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 11.6% during the third quarter, Holdings Channel reports. The institutional investor owned 290,350 shares of the biotechnology company’s stock after selling 38,270 shares during the period. Capital Management Corp VA’s holdings in Anika Therapeutics were worth $7,172,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Eastern Bank acquired a new stake in shares of Anika Therapeutics in the third quarter valued at $28,000. Lazard Asset Management LLC acquired a new stake in Anika Therapeutics in the 1st quarter valued at about $180,000. State Board of Administration of Florida Retirement System acquired a new stake in Anika Therapeutics in the 1st quarter valued at about $198,000. SG Americas Securities LLC boosted its position in shares of Anika Therapeutics by 7.8% during the 1st quarter. SG Americas Securities LLC now owns 8,615 shares of the biotechnology company’s stock valued at $219,000 after purchasing an additional 627 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Anika Therapeutics by 16.9% in the 1st quarter. BNP Paribas Financial Markets now owns 22,240 shares of the biotechnology company’s stock worth $565,000 after purchasing an additional 3,217 shares in the last quarter. 91.53% of the stock is owned by institutional investors and hedge funds.

Anika Therapeutics Trading Up 3.3 %

Shares of ANIK opened at $17.07 on Tuesday. Anika Therapeutics, Inc. has a one year low of $16.00 and a one year high of $29.11. The company has a 50-day moving average of $24.45 and a two-hundred day moving average of $25.58.

Anika Therapeutics (NASDAQ:ANIK) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.24). The firm had revenue of $41.92 million for the quarter, compared to analyst estimates of $39.90 million. Anika Therapeutics had a negative net margin of 59.40% and a negative return on equity of 2.22%. During the same period last year, the firm earned ($0.06) earnings per share. Equities analysts forecast that Anika Therapeutics, Inc. will post -0.1 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on ANIK shares. StockNews.com lowered shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday. Barrington Research cut their price objective on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a research report on Friday.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.